Executive Director, Oncology Access

Overview:

Executive Director, Oncology Access

Reports to Vice President, Head of US Market Access

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 140 countries around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. ELZONRIS® (tagraxofusp) is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). To date, Elzonris is the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelofibrosis (MF).

In Europe, Menarini Stemline also commercializes Nexpovio®, a first-in-class oral exportin 1 (XPO1) inhibitor for multiple myeloma in the UK, Switzerland, European Economic Area, CIS countries, Latin America and Turkey. Nexpovio is approved for use in combination with dexamethasone for treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy; and in combination with bortezomib and dexamethasone for treatment of adult patients with multiple myeloma who have received at least one prior therapy. Nexpovio’s marketing authorization is valid in the EU Member States as well as Iceland, Liechtenstein, Norway, and Northern Ireland, and it has been commercially available in Germany and Austria since the fourth quarter of 2022.

In January 2023, Stemline Therapeutics, received U.S. FDA approval for ORSERDU™ (elacestrant), the first and only treatment specifically indicated for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. ESR1 mutations cause tumors to become resistant to endocrine therapy, and up to 40% of patients with ER+, HER2- mBC have tumors which harbor this mutation. ORSERDU is the first endocrine innovation in more than 20 years, and specifically addresses a major unmet need. Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies. A Marketing Authorization Application (MAA) is currently under review by the European Medicines Agency (EMA).

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions.   MSB’s CELLSEARCH Circulating Tumor Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB is offering in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

Opportunity

The Executive Director, Oncology Access is responsible for leading and developing the Oncology access team who is accountable for removing clinical, financial, and operational barriers across sGPO, provider network, and target national provider accounts (Academic and Community).  This role will also be accountable for orchestrating the overall strategy and positioning Menarini Stemline as a current/future leader in Oncology for the following customer segments/channels in coordination with necessary internal stakeholders (brand teams, sales, finance, operations, etc.).

• Specialty Group Purchasing Organizations
• Physician Network Groups (e.g. Florida Cancer, Tennessee Oncology)
• Priority IDN/Centers of Excellence
• Oncology State Societies

Responsibilities

• Lead the team and influences internal organization, and other stakeholders.
• Manage performance and addresses skill development for direct reports to ensure appropriate business management.
• Develop and maintain strong working relationships with C-Suite and influential leaders in senior management with a goal of understanding unique business needs and strategic challenges of the customers.
• As needed, present business cases for opportunities/evaluation including a broad view of the enterprise impact.
• Inform dispensing and distribution strategies with insights from customers.
• Ensure that appropriate performance metrics are included in account plans and are being reported across the organization.
• When account specific issues and challenges are identified, engage with appropriate internal resources to assist
• Provide strategic input to key internal stakeholders on account segments.
• Monitor and maintain a high level of awareness of pricing regulations and third-party reimbursement policies.
• Partner with internal cross functional partners to appropriately achieve business objectives and resolve account related issues.
• Represent Stemline at key conferences and vendor functions, which impact relationships with key customers.
• Act as a subject matter expert on payer environments including PBM and payer owned pharmacies.
• Maintain an outstanding level of knowledge of pull through opportunities, program development, projected impact, and implementation techniques.
• In addition, the role is responsible for conducting business in accordance with all appropriate company policies.

Competencies and job qualifications

• Technical:
  • In-depth knowledge of product prescribing information
  • Well-developed negotiation skills.
  • A high level of awareness and understanding of the implications and opportunities of contract strategy.
  • A thorough knowledge of strategic marketing and selling.
  • An in-depth knowledge of key account selling for targeted channels/segments.
  • Proficiency with software applications and customer relationship management tools (where applicable).
  • A high level of knowledge of current reimbursement modalities, including AWP, WAC, ASP, margin, spread, and MAC pricing.
  • A thorough understanding of all corporate policies and procedures.
  • Thorough understanding of Patient Support and Services.
  • An in-depth knowledge of the marketplace and applies that understanding to targeted account segment marketing, distribution strategy development and implementation to accomplish business objectives.
  • The ability to influence key decision makers in targeted account segments.
  • Manage expenses within set budgetary guidelines

• Communication:
  • Strong oral, written, and group communication skills with internal and external customers.
  • Effective communication with targeted national accounts including C-suite customers.
  • In a timely and accurate manner, submit all budgetary information, expense reports and administrative reports as requested.

Required Experience

• Bachelor's degree required, advanced business or science degree desirable.
• 15+ years in Pharmaceutical Industry
• Experience and demonstrated success leading strategic account teams in a matrixed organization
• Minimum 8 years work experience within various areas of market access.
• Demonstrated success in finding the point of intersection between customer and business priorities
• Thorough understanding of market dynamics across multiple therapeutic areas (oncology/hematology preferred) and across various business segments
• Ability to develop and maintain strong business partnerships with C-Suite and influence leaders in senior management within Key Accounts.
• Understanding of the entire Key account segment/channels including payor, trade distribution network, and specialty pharmacy providers.
• Team player and self-starter with a constructive attitude.
• Must have a “roll-up their sleeves” work style understanding both tactical and strategic work requirements
• Overnight travel of 30% may be required.

Stemline Therapeutics is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.  All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.